Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials
C2000-2021 InvestorIdeas.com tm
Read more: https://www.investorideas.com/news/2024/biotech/09261Pasithea-Therapeutics-KTTA.asp
Text source: Investorideas.com newswire, breaking stock market